Clinical Trial Update: An Observational Study of the Mean Duration of Trastuzumab (Herceptin) Treatment in Participants With Early or Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer

View source ↗

Summary

This clinical trial update reports results from an observational study evaluating the mean duration of trastuzumab (Herceptin) treatment in patients with early …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• HERCEPTIN (trastuzumab)

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Breast Cancer | Status: TERMINATED | Results posted: 2017-10-20